Inventor · disambiguated record
Wenzhi Tian
Also filed as: TIAN WENZHI
9 granted patents·9 pending applications·19 citations·filing 2007–2024
82Inventor score
Files withIMMUNEONCO BIOPHARMACEUTICALS SHANGHAI CO LTD10IMMUNEONCO BIOPHARMACEUTICALS SHANGHAI INC7LIOU HSIOU-CHI1
Top patents by PatentIndex Score
18 records- 0192US11672859B2Recombinant fusion proteins targeting CD47 and PD-L1, preparation and use thereofIMMUNEONCO BIOPHARMACEUTICALS SHANGHAI INC·Filed 2021·Granted Jun 13, 2023·3 cites·15 claims
- 0290US11613584B1Antibodies binding CD70, preparation and use thereofIMMUNEONCO BIOPHARMACEUTICALS SHANGHAI INC·Filed 2022·Granted Mar 28, 2023·8 cites·16 claims
- 0387US10800821B2Recombinant bi-functional fusion protein and preparation and application thereforIMMUNEONCO BIOPHARMACEUTICALS SHANGHAI CO LTD·Filed 2015·Granted Oct 13, 2020·5 cites·13 claims
- 0479US2025127855A1Combination Therapy for CMML and MDSIMMUNEONCO BIOPHARMACEUTICALS SHANGHAI INC·Filed 2023·Application pending·0 cites
- 0576US10973878B2Recombinant fusion protein containing an anti-PD-L1 antibodyIMMUNEONCO BIOPHARMACEUTICALS SHANGHAI CO LTD·Filed 2018·Granted Apr 13, 2021·2 cites·8 claims
- 0673US11407832B2Recombinant protein targeting PD-L1 and VEGFIMMUNEONCO BIOPHARMACEUTICALS SHANGHAI CO LTD·Filed 2019·Granted Aug 9, 2022·1 cites·8 claims
- 0767US2021388043A1Recombinant bi-functional fusion proteins binding cd47 and fc gamma receptor, preparation and use thereofIMMUNEONCO BIOPHARMACEUTICALS SHANGHAI CO LTD·Filed 2021·Application pending·0 cites
- 0864US2025332216A1Combination therapy for classic hodkin's lymphomaIMMUNEONCO BIOPHARMACEUTICALS SHANGHAI INC·Filed 2024·Application pending·0 cites
- 0963US11453724B2Recombinant bifunctional protein targeting CD47 and HER2IMMUNEONCO BIOPHARMACEUTICALS SHANGHAI CO LTD·Filed 2019·Granted Sep 27, 2022·0 cites·10 claims
- 1062US2022010031A1Novel recombinant bi-functional fusion protein, preparation method therefor and use thereofIMMUNEONCO BIOPHARMACEUTICALS SHANGHAI CO LTD·Filed 2021·Application pending·0 cites
- 1162US2021024598A1Novel recombinant bi-functional fusion protein and preparation and application thereforIMMUNEONCO BIOPHARMACEUTICALS SHANGHAI CO LTD·Filed 2020·Application pending·0 cites
- 1262US2021380716A1Recombinant bifunctional protein targeting cd47 and her2IMMUNEONCO BIOPHARMACEUTICALS SHANGHAI CO LTD·Filed 2021·Application pending·0 cites
- 1360US11407841B2Recombinant bi-functional fusion protein and use thereofIMMUNEONCO BIOPHARMACEUTICALS SHANGHAI CO LTD·Filed 2018·Granted Aug 9, 2022·0 cites·8 claims
- 1459US2023167194A1Recombinant bifunctional protein targeting cd47 and her2IMMUNEONCO BIOPHARMACEUTICALS SHANGHAI INC·Filed 2022·Application pending·0 cites
- 1557US2023110702A1Recombinant fusion proteins targeting cd47 and cd38, preparation and use thereofIMMUNEONCO BIOPHARMACEUTICALS SHANGHAI CO LTD·Filed 2022·Application pending·0 cites
- 1655US11926675B2Antibodies binding CD24, preparation and use thereofIMMUNEONCO BIOPHARMACEUTICALS SHANGHAI INC·Filed 2022·Granted Mar 12, 2024·0 cites·14 claims
- 1755US11891449B2Recombinant fusion proteins targeting CD47 and CD24, preparation and use thereofIMMUNEONCO BIOPHARMACEUTICALS SHANGHAI INC·Filed 2021·Granted Feb 6, 2024·0 cites·18 claims
- 1850US2010055116A1Methods and Compositions for Targeting c-RelLIOU HSIOU-CHI·Filed 2007·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Wenzhi Tian files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →